University of Crete (UOC)
Πολυκεντρική, κλινική, εργαστηριακή και επιδημιολογική διερεύνηση της λεϊσμανίασης στην Ελλάδα
Abstract
dc:descriptionIntroduction – Theoretical background: Leishmaniasis is caused by protozoa of the genus Leishmania and is transmitted to humans through the bite of infected phlebotomine sandflies. In the Mediterranean region, it is mainly associated with Leishmania infantum and is characterized by zoonotic transmission with the dog as the principal reservoir; it has also been linked to Leishmania tropica. The disease is classified into visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). Despite its endemicity in Greece, available data have been fragmented, largely limited to small, single-center case series. Moreover, the increasing number of immunocompromised patients has altered the contemporary epidemiology of the disease. The present dissertation aims to address this gap through a multicenter, systematic recording and analysis of cases at a national level. Aim – Research questions: The aim of the study was to conduct a systematic, multicenter clinical, laboratory, and epidemiological investigation of leishmaniasis in Greece, with emphasis on both visceral and cutaneous forms. The specific objectives were:•To record demographic and epidemiological characteristics;•To analyze clinical presentation and laboratory findings;•To evaluate diagnostic methods;•To document therapeutic strategies;•To investigate treatment outcomes, relapses, and mortality;•To compare immunocompetent and immunocompromised patients.The primary research questions were:•What is the contemporary clinical and epidemiological profile of leishmaniasis in Greece?•Which factors are associated with treatment failure or relapse?•How does immunosuppression affect clinical presentation and prognosis?•Are there indirect indications of reduced susceptibility to anti-leishmanial drugs? Materials – Methods: Study design: Multicenter observational study with a mixed (retrospective and prospective) approach.Study period: January 1994 – December 2019 (26 years). Participating centers: Seven public hospitals in Greece. Study population: Patients with laboratory-confirmed VL or CL.Demographic data, underlying diseases, immunosuppressive factors, clinical and laboratory findings, diagnostic methods, treatment regimens, and outcomes were recorded. Descriptive and analytical statistical analyses were performed (primarily for VL). Results: Visceral leishmaniasisTotal number of patients: 144 (142 exclusively with VL and 2 with concomitant VL and CL). Fifty-nine percent were male and 85% were Greek nationals.Clinical characteristics: Prolonged fever (95%), weakness (60%), rigors (45%), splenomegaly (88%), hepatomegaly (53%), anemia (85%), thrombocytopenia (77%), leukopenia (72%), pancytopenia (58%), and polyclonal hypergammaglobulinemia (70%). Diagnostic methods: Parasitological confirmation was achieved in 68 patients, serology in 121 patients, and Polymerase Chain Reaction (PCR) in 71 patients. Parasite culture was successfully performed in 33 cases. Treatment: Liposomal amphotericin B (L-AmB) was the main therapeutic option and was administered to 90.2% of patients, at higher doses in immunocompromised individuals. The use of pentavalent antimonial compounds was limited (3.5%) due to toxicity. Outcome: An unfavorable outcome was recorded in 14 patients after initial therapy: two patients had persistent fever, eight experienced relapse within 18 months, and four died during the initial hospitalization (one death directly attributed to VL). An additional three deaths were recorded during the follow-up period.Comparison by immune status: One hundred and two patients were classified as immunocompetent and 42 as immunocompromised. The mean age of immunocompromised patients was significantly higher than that of immunocompetent patients (57.5 ± 21.2 years vs. 35.3 ± 25.8 years, p < 0.001). Sex distribution differed between groups, with a higher proportion of males among immunocompetent patients (65% vs. 45%, p = 0.031). Regarding clinical presentation, arthralgia (21% vs. 9%, p = 0.038) and diarrhea (21% vs. 8%, p = 0.022) were more frequently observed in immunocompromised patients. In contrast, hepatomegaly was more common in immunocompetent patients (62% vs. 33%, p = 0.002). Trends toward higher frequency of weakness and longer symptom and fever duration were also observed among immunocompromised patients, although these findings were not statistically significant. Unfavorable outcome was more frequent among immunocompromised patients according to univariate analysis. Specifically, 57% of patients with unfavorable outcome were immunocompromised compared to 26% among those with favorable outcome (p = 0.027). Among individual immunosuppressive conditions, leukemia was strongly associated with unfavorable outcome (21% vs. 0%, p < 0.001). Relapse within 18 months after treatment completion was more frequent among immunocompromised patients; however, statistical significance was not established due to the small number of events. Mortality was numerically higher in immunocompromised patients, although the difference did not reach statistical significance. Cutaneous leishmaniasisTotal number of patients: 25 (23 exclusively with CL and 2 with concomitant CL and VL). The mean age was 50.3 ± 22.1 years; 56% were male. Twenty-two patients were Greek nationals.Clinical presentation: Single (13 patients) or multiple (12 patients) skin lesions with a mean duration of 327 days. Lesions were ulcerative (36%), nodular (28%), or plaque-like (28%) and were mainly located on exposed body areas (80%). Diagnosis was established by PCR in 16 patients and by biopsy in 13 patients. Parasite culture was successfully performed in seven cases. Therapeutic approach: Local treatment (intralesional injections or cryotherapy) was selected for patients with a limited number of lesions and mild clinical presentation. Systemic therapy with fluconazole, L-AmB, or pentavalent antimonial compounds was administered in selected cases (multiple lesions, extensive disease, facial involvement, immunosuppression). In a small number of patients, a conservative approach with close clinical follow-up was adopted. Outcome: Treatment failure was recorded in three patients; two were subsequently managed with an alternative therapeutic regimen, while repeat biopsy in one patient revealed basal cell carcinoma adjacent to the active leishmanial lesion. Four relapses were recorded, associated with immunosuppression or comorbidities. All patients ultimately responded to systemic therapy. No deaths directly related to CL were recorded.Discussion: This study provides real-world clinical data from 26 years of systematic case recording. It highlights the evolving epidemiology of the disease, the significant impact of immunosuppression, the effectiveness of L-AmB, the need for increased diagnostic vigilance, and the importance of long-term follow-up in high-risk groups. Conclusions: This dissertation represents the most comprehensive multicenter recording of leishmaniasis in Greece to date. It documents the contemporary clinical and epidemiological profile of the disease, underscores the pivotal role of immunosuppression in prognosis, confirms the high effectiveness of modern therapeutic approaches, and highlights the need for systematic surveillance and targeted follow-up. The study has direct clinical and public health significance and may contribute to optimizing diagnostic and therapeutic strategies in the Greek setting.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Aristodimou, Aristos
- Αριστοδήμου, Άριστος
Subjects
dc:subject × 14- Σπλαγχνική Λεϊσμανίαση
- Δερματική λεϊσμανίαση
- Ανοσοκαταστολή
- Παράγοντες κινδύνου λοίμωξης
- Visceral leishmaniasis
- Cutaneous leishmaniasis
- Immunosuppression
- Risk factor analysis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Γενική και Εσωτερική ιατρική
- Clinical Medicine
- Medical and Health Sciences
- General and Internal Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62124